Compare SKYT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | PRCT |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2021 |
| Metric | SKYT | PRCT |
|---|---|---|
| Price | $27.74 | $26.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $26.50 | ★ $35.44 |
| AVG Volume (30 Days) | 872.7K | ★ 2.1M |
| Earning Date | 05-26-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1842.86 | 1.71 |
| EPS | ★ 2.44 | N/A |
| Revenue | ★ $442,139,000.00 | $308,054,000.00 |
| Revenue This Year | $40.53 | $32.85 |
| Revenue Next Year | $4.01 | $24.66 |
| P/E Ratio | $10.74 | ★ N/A |
| Revenue Growth | 29.18 | ★ 37.22 |
| 52 Week Low | $5.67 | $19.35 |
| 52 Week High | $36.07 | $64.89 |
| Indicator | SKYT | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 47.08 |
| Support Level | $14.54 | $19.35 |
| Resistance Level | $31.19 | $29.24 |
| Average True Range (ATR) | 1.06 | 2.15 |
| MACD | -0.23 | 0.21 |
| Stochastic Oscillator | 1.49 | 73.40 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.